false FY 0001424768

 2023-06-30

 2024-04-16

 us-gaap: NonrelatedPartyMember

 us-gaap: NonrelatedPartyMember

 us-gaap: RelatedPartyMember

 us-gaap: RelatedPartyMember

 us-gaap: RelatedPartyMember

 us-gaap: RelatedPartyMember

 us-gaap: NonrelatedPartyMember

 us-gaap: NonrelatedPartyMember

 us-gaap: PatientAccountsReceivableMember

 us-gaap: PatientAccountsReceivableMember

 VYCO:DebenturesConvertibleIntoCommonStockMember

 VYCO:DebenturesConvertibleIntoCommonStockMember

 VYCO:PreferredSharesConvertibleToCommonStockMember

 VYCO:PreferredSharesConvertibleToCommonStockMember

 VYCO:FountainheadCapitalManagementLimitedMember

 VYCO:FountainheadCapitalManagementLimitedMember

 VYCO:InsurancePolicyFinanceAgreementsMember

 VYCO:InsurancePolicyFinanceAgreementsMember

 VYCO:EconomicInjuryDisasterLoanProgramMember
 VYCO:CaresActMember

 VYCO:EconomicInjuryDisasterLoanProgramMember
 VYCO:CaresActMember

 2018-06-25

 2018-06-24
 2018-06-25

 VYCO:FountainheadCapitalManagementLimitedMember

 2022-11-17

 VYCO:FountainheadCapitalManagementLimitedMember

 2018-03-26
 2022-11-17

 2011-03-25

 us-gaap: ExtendedMaturityMember

 2011-03-25
 2011-03-25

 VYCO:EconomicInjuryDisasterLoanProgramMember
 VYCO:CaresActMember

 2020-07-07

 VYCO:EconomicInjuryDisasterLoanProgramMember
 VYCO:CaresActMember

 2020-07-06
 2020-07-07

 VYCO:AmendmentAgreementMember

 2018-01-24

 VYCO:AmendmentAgreementMember

 2018-01-23
 2018-01-24

 VYCO:BusinessSegmentMember

 VYCO:GeographicSegmentsMember

 VYCO:VycorMedicalMember

 VYCO:VycorMedicalMember

 VYCO:NovaVisionMember

 VYCO:NovaVisionMember

 us-gaap: CorporateMember

 us-gaap: CorporateMember

 VYCO:VycorMedicalMember

 VYCO:VycorMedicalMember

 VYCO:NovaVisionMember

 VYCO:NovaVisionMember

 us-gaap: SegmentDiscontinuedOperationsMember

 us-gaap: SegmentDiscontinuedOperationsMember

 country: US

 country: US

 srt: EuropeMember

 srt: EuropeMember

 country: US

 country: US

 srt: EuropeMember

 srt: EuropeMember

 us-gaap: MachineryAndEquipmentMember

 us-gaap: MachineryAndEquipmentMember

 us-gaap: LeaseholdImprovementsMember

 us-gaap: LeaseholdImprovementsMember

 VYCO:PurchasedSoftwareMember

 VYCO:PurchasedSoftwareMember

 us-gaap: ToolsDiesAndMoldsMember

 us-gaap: ToolsDiesAndMoldsMember

 us-gaap: FurnitureAndFixturesMember

 us-gaap: FurnitureAndFixturesMember

 VYCO:TherapyDevicesMember

 VYCO:TherapyDevicesMember

 VYCO:InternallyDevelopedSoftwareMember

 VYCO:InternallyDevelopedSoftwareMember

 VYCO:TherapyDevicesMember

 VYCO:TherapyDevicesMember

 VYCO:ConsultantMember
 VYCO:RicardoKomotarMember
 VYCO:ConsultingAgreementMember

 2023-04-01
 2023-04-02

 VYCO:ConsultantMember
 VYCO:RicardoKomotarMember
 VYCO:ConsultingAgreementMember

 2022-04-01
 2022-04-02

 VYCO:ConsultingAgreementMember

 VYCO:ConsultingAgreementMember

 VYCO:SeriesConvertibleCPreferredStockMember

 VYCO:SeriesConvertibleCPreferredStockMember

 VYCO:SeriesConvertibleDPreferredStockMember

 VYCO:SeriesConvertibleDPreferredStockMember

 VYCO:NonemployeesMember

 VYCO:NonemployeesMember

 VYCO:MarchTwoThousandSeventeenandEffectiveAprilOneTwoThousandSeventeenMember

 VYCO:NonemployeeDirectorsMember
 VYCO:DirectorsDeferredCompensationPlanMember

 us-gaap: DomesticCountryMember

 us-gaap: DomesticCountryMember

 us-gaap: ForeignCountryMember

 us-gaap: ForeignCountryMember

 2017-12-22
 2017-12-22

 country: DE

 country: DE

 country: GB

 country: GB

 country: DE

 country: DE

 country: GB

 country: GB

 VYCO:OfficeSpaceMember

 2012-06-30

 2012-06-29
 2012-06-30

 2016-10-31

 2016-10-29
 2016-10-31

 2017-03-01
 2017-03-31

 2017-03-31

 VYCO:EffectiveJanuaryOneTwoThousandTwentyOneMember

 VYCO:EffectiveJanuaryOneTwoThousandTwentyOneMember

 VYCO:ConsultancyAgreementMember

 VYCO:ConsultancyAgreementMember

 VYCO:GeneralConsultancyMember

 2021-03-24
 2021-03-30

 2021-03-24
 2021-03-30

 2023-04-01

 2022-04-01

 2023-04-01
 2023-04-01

 2022-04-01
 2022-04-01

 VYCO:DirectorsMember

 VYCO:DirectorsMember

 VYCO:ChairmanMember

 VYCO:ChairmanMember

 VYCO:UnsecuredLoanMember

 VYCO:UnsecuredLoanMember

 VYCO:UnsecuredLoanMember

 VYCO:UnsecuredLoanMember

 us-gaap: SalesRevenueNetMember

 us-gaap: SalesRevenueNetMember

 VYCO:CustomerOneMember
 us-gaap: SalesRevenueNetMember

 VYCO:CustomerOneMember
 us-gaap: SalesRevenueNetMember

 us-gaap: AccountsReceivableMember

 us-gaap: AccountsReceivableMember

 VYCO:CustomerOneMember
 us-gaap: AccountsReceivableMember

 VYCO:CustomerOneMember
 us-gaap: AccountsReceivableMember

 VYCO:ManufacturerThreeMember
 VYCO:PurchaseMember

 VYCO:ManufacturerThreeMember
 VYCO:PurchaseMember

 VYCO:Integer

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 Washington,
D.C. 20549

 Form

 ANNUAL
 REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the fiscal year ended December 31, 2023

 Or

 TRANSITION
 REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the transition period from ___________ to ___________

 Commission
file number: 001-34932

 VYCOR

 (Exact
name of registrant as specified in charter)

 Delaware

 20-3369218

 (State
 or other jurisdiction of

 (I.R.S.
 Employer

 incorporation
 or organization)

 Identification
 No.)

Broken Sound Boulevard, Suite, 320 Boca Raton, FL 33487

 (Address
of principal executive offices) (Zip Code)

 Registrant's
telephone Number: ( 561) 558-2020

 Securities
registered pursuant to Section 12(b) of the Act:

 Title
 of each class

 Trading
 Symbol

 Name
 of each exchange on which registered

 Common
 Stock

 VYCO

 OTCQB

by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes
 No

by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes No

by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files). Yes No

by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K.

by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of "large accelerated filer", "accelerated filer", "non-accelerated filer",
and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

 Large
 Accelerated Filer

 Accelerated
 Filer

 Non-accelerated
 Filer (Do not check if a smaller reporting company)

 Smaller
 Reporting Company

 Emerging
 Growth Company

by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 State
the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's
most recently completed second fiscal quarter. $ 1,174,147 (assuming $0.10 per share)

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date 32,628,835
shares of common stock par value $0.0001 as of April 16, 2024

 DOCUMENTS
INCORPORATED BY REFERENCE: NONE

 TABLE
OF CONTENTS

 Page

 Item
 1.

 Business

 Item
 1A

 Risk Factors

 Item
 1B

 Unresolved Staff Comments

 Item
 2.

 Properties

 Item
 3.

 Legal Proceedings

 Item
 4.

 Mine Safety Disclosures

 Item
 5.

 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchase of Equity Securities

 Item

 Selected Financial Data

 Item
 7.

 Management's Discussion and Analysis of Financial Condition and Results of Operation

 Item
 7A

 Quantitative and Qualitative Disclosures About Market Risk

 Item
 8.

 Financial Statements and Supplementary Data

 Item
 9.

 Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

 Item
 9A.

 Controls and Procedures

 Item
 9B.

 Other Information

 Item
 10.

 Directors, Executive Officers, Promoters and Corporate Governance

 Item
 11.

 Executive Compensation

 Item
 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item
 13.

 Certain Relationships and Related Transactions, and Director Independence

 Item
 14.

 Principal Accountant Fees and Services

 Item
 15.

 Exhibits, Financial Statement Schedules

 SIGNATURES

 PART
I

 This
Form 10-K contains some forward-looking statements. Forward-looking statements give our current expectations or forecasts of future events.
You can identify these statements by the fact that they do not relate strictly to historical or current facts. Forward-looking statements
involve risks and uncertainties. Forward-looking statements include statements regarding, among other things, (a) our projected sales,
profitability, and cash flows, (b) our growth strategies, (c) anticipated trends in our industries, (d) our future financing plans and
(e) our anticipated needs for working capital. They are generally identifiable by use of the words "may," "will,"
"should," "anticipate," "estimate," "plans," "potential," "projects,"
"continuing," "ongoing," "expects," "management believes," "we believe,"
"we intend" or the negative of these words or other variations on these words or comparable terminology. These statements
may be found under "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business,"
as well as in this Form 10-K generally. In particular, these include statements relating to future actions, prospective products or product
approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such
as legal proceedings, and financial results.

 Any
or all of our forward-looking statements in this report may turn out to be inaccurate. They can be affected by inaccurate assumptions
we might make or by known or unknown risks or uncertainties. Consequently, no forward-looking statement can be guaranteed. Actual future
results may vary materially as a result of various factors, including, without limitation, the risks outlined under "Risk Factors"
and matters described in this Form 10-K generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking
statements contained in this filing will in fact occur. You should not place undue reliance on these forward-looking statements.

 The
forward-looking statements speak only as of the date on which they are made, and, except to the extent required by federal securities
laws, we undertake no obligation to publicly update any forward-looking statements, whether as the result of new information, future
events, or otherwise.

 ITEM
1. DESCRIPTION OF BUSINESS.

 1.
Organizational History

 The
Company was formed as a limited liability company under the laws of the State of New York on June 17, 2005 as "Vycor Medical LLC".
On August 14, 2007, we converted into a Delaware corporation and changed our name to "Vycor Medical, Inc." ("Vycor").
The Company's listing went effective on February 2009 and on November 29, 2010 Vycor completed the acquisition of substantially
all of the assets of NovaVision, Inc. ("NovaVision") and on January 4, 2012 Vycor, through its wholly-owned NovaVision subsidiary,
completed the acquisition of all the shares of Sight Science Limited ("Sight Science"), a previous competitor to NovaVision.

 2.
Overview of Business

 Vycor
is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and operates two distinct
business units within the medical device industry. Vycor Medical designs, develops and markets medical devices for use in neurosurgery.
NovaVision provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage
such as that caused by a stroke. Both businesses adopt a minimally or non-invasive approach. The Company leverages joint resources across
the divisions to operate in a cost-efficient manner.

 The
Company periodically engages in discussions with potential strategic partners for or purchasers of each or both of our operating divisions.
In April 2020, the board of Vycor took the decision to close the German operations of NovaVision, including the German office and NovaVision
GmbH, and instead migrate to a licensed business model, entering into a license agreement with a local German partner. Under the agreement,
the partner is licensed to provide NovaVision's products and therapies in Germany, Austria and Switzerland to patients and professionals.
The NovaVision German office was closed effective June 30, 2020.

 Vycor
Medical

 Vycor
Medical designs, develops and markets medical devices for use in neurosurgery. Vycor Medical's ViewSite Brain Access System ("VBAS")
is a next generation retraction and access system. Vycor Medical is ISO 13485:2016 and MDSAP (Medical Device Single Audit Program) certified,
and VBAS has U.S. FDA 510(k) clearance and CE Marking for Europe (Class III) for brain and spine surgeries, and regulatory approvals
in a number of other international markets.

provides non-invasive, computer-based rehabilitation therapies targeted at people who have impaired vision as a result of stroke or other
brain injury.

 Strategy

 The
Company is continuing to execute on a plan to achieve revenue growth and a reduction in annual cash operating losses, and
generated cash operating income for the year ended December 31, 2023. For Vycor Medical this plan includes: increasing market penetration
in the US; increasing international growth in territories where we are not represented or under-represented and continued new product
development in response to market demands and demonstrating applicability in a broader range of pathologies. In the US the Company is
focused on increasing market penetration through targeting neurosurgeons systematically, both through its distribution and marketing
network and also directly by leveraging existing key opinion leader ("KOL") neurosurgeon VBAS supporters to access new neurosurgeon
users.

 The
Company has for some time been working to better integrate its VBAS with neuronavigation. The first phase of the modification of the
existing VBAS product range was completed in September 2017 and was well received by surgeons. The second phase involved the introduction
of an optional Alignment Clip accessory that snaps onto the VBAS and allows for a neuronavigation pointer to be fully integrated into
the body of the VBAS; this new model range, known as the VBAS AC, was launched in September 2022, with the international roll-out being
largely complete by the end of 2023. The Company will continue to work with neuronavigation companies to seek ways to further integrate
the VBAS with neuronavigation and with other companies with complementary technologies used in neurosurgery. We will also be exploring
with neurosurgeons and focus groups additional selected development work targeted at increasing the ease and applicability of our products
to additional common procedures.

 For
NovaVision, given the company's resources, and the large size and diversity of its end markets, we believe that the most efficient
way to tackle the distribution of its broad range of patient and professional products is by partnering with entities in selected geographies
that have either direct access to the end users or a desire and financial wherewithal to leverage the NovaVision therapy platform, including
into new areas. As a result, the Company closed the NovaVision German office and entered into a license agreement with a local German
for Germany, Austria and Switzerland. Management is also open to a broad range of alternatives for NovaVision as a whole, which could
comprise distribution and marketing partnerships, licensing, merger or sale.

 3.
Other Matters

 Product
Liability Insurance

 We
presently have Product Liability insurance for Vycor Medical and Professional Liability insurance for NovaVision.

 Government
Regulations

 We
are committed to an integrated total quality management system. We believe that we have completed the necessary procedures and Vycor
Medical is certified to the ISO standards expected of medical device manufacturers as follows:

 ISO
13485:2016 Medical Devices — Quality Management Systems

 The
certification of a quality management system to ISO 1348:2016, specifically for medical devices, is advantageous and often essential
for medical companies to export their products to the global market, as well as maintain and enter into certain agreements and business
growth opportunities within the U.S. For example, Canada requires that medical device manufacturers marketing their products in Canada
must have a quality system certified to ISO 13485:2016 and from January 1, 2019 also be certified to MDSAP. The certification is also
required for placement of branded devices into the European Union.

 Vycor
Medical has the following certification/licensing:

 ISO
 13485.2016

 MDSAP
 (Medical Device Single Audit Program)

 Fully
 Quality Assurance System Directive 93/42/EEC for Medical Devices, Annex II (3)

 EC
 Design-Examination Certificate Directive 93/42/EEC for Medical Devices, Annex II (4)

 Vycor
Medical's VBAS and VBAS AC have been classified as Class II products by the FDA and cleared for marketing through the 510(k) process.
NovaVision's VRT product has been cleared as a Class U product through the 510(k) while its NeuroEyeCoach is registered as an exempt
Class 1 device.

 Vycor
Medical has CE marking approval to allow for distribution of its VBAS products in Europe as a Class III device and has a Health Canada
Medical Device License (MDL) for distribution in Canada as a Class II device. VBAS also has regulatory approvals in a number of other
international markets. NovaVison's VRT, NeuroEyeCoach and Sight Science's NeET have CE mark registrations as Class I devices
in Europe.

 Employees

 We
currently have 8 employees.

 Website.

 The
Company operates websites at www.vycormedical.com, www.vycorvbas.com, and www.novavision.com. NovaVision's German partner maintains
the www.novavision.de website.

 ITEM
1A. RISK FACTORS

 Smaller
reporting companies are not required to provide the information required by this item.

 ITEM
1B. UNRESOLVED STAFF COMMENTS

 N/A

 ITEM
2. PROPERTIES

 The
Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent
of approximately $4,300 per month, plus other charges of approximately $2,700 per month. The lease terminated on August 31, 2023 and
was extended for a further three years and four months to December 31, 2026

 ITEM
3. LEGAL PROCEEDINGS

 We
are subject from time to time to litigation, claims and suits arising in the ordinary course of business. As of the date of this Annual
Report, we were not a party to any material litigation, claim or suit whose outcome could have a material effect on our financial statements.

 ITEM
4. MINE SAFETY DISCLOSURES

 Not
applicable

 PART
II

 ITEM
5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

 Market
Information

 Beginning
on July 20, 2009, our Common Stock was quoted on the OTC Bulletin Board under the symbol "VYCO".

 The
market price of our common stock, like that of other early-stage medical device companies, is highly volatile and is subject illiquidity
and to fluctuations in response to variations in operating results, announcements of technological innovations or new products, or other
events or factors.

 Holders

 As
of April 16, 2024 and April 12, 2023 there were 32,628,835 shares of common stock issued and outstanding and approximately 129 stockholders
of record.

 Transfer
Agent and Registrar

 Our
transfer agent is EQ by Equiniti, 1110 Centre Pointe Curve, Suite 101, Mendota Heights, MV 55120

 Dividend
Policy

 We
have never paid any cash dividends on our Common Stock and do not anticipate paying any cash dividends on our Common Stock in the foreseeable
future. We intend to retain future earnings to fund ongoing operations and future capital requirements of our business. Any future determination
to pay cash dividends will be at the discretion of the Board of Directors and will be dependent upon our financial condition, results
of operations, capital requirements and such other factors as the Board of Directors deems relevant. The Company's Series D Convertible
Preferred Stock bears a 12% per annum dividend payable in cash or Series D Preferred Stock at the option of the Company.

 RECENT
SALES OF UNREGISTERED SECURITIES

 Below
is a list of securities sold by us from January 1, 2023 through April __, 2024 which were not registered under the Securities Act

 Common
Stock:

 Issuance Type

 Security

 Security

 Ricardo Komotar (1)

 Common

 101,663

 (1)
Consulting fees paid in connection with a Consulting Agreement between the Company and the holder

 The
securities issued in the above-mentioned transactions were issued in connection with private placements exempt from the registration
requirements of Section 5 of the Securities Act of 1933, as amended, pursuant to the terms of Section 4(2) of that Act and Rule 506 of
Regulation D.

 ITEM
6. SELECTED FINANCIAL DATA

 Not
applicable

 ITEM
7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.

 RESULTS
OF OPERATIONS

 Comparison
of the Year Ended December 31, 2023 to the Year Ended December 31, 2022

and Gross Margin:

 Vycor
Medical recorded revenue of $1,378,598 from the sale of its products for the year ended December 31, 2023, an increase of $247,683 (or
22%) over 2022. Most of the increase was accounted for by the US, which grew by 23% over 2022 due to increased penetration and hospital
usage, with the rest being Other International, offset by a slight decline in Europe. Gross margin of 90% was recorded for the year ended
December 31, 2023 compared to 88% in 2022.

recorded revenues of $82,006 for the year ended December 31, 2023, a decrease of $10,068 from 2022, and gross margin of 94%, compared
to 92% for 2022.

 Research
& Development:

 Research
& Development expenses were $22,558 for the year ended December 31, 2023 compared to $0 for the year ended December 31, 2022, reflecting
early-stage product development for the Vycor division.

 Selling,
General and Administrative Expenses:

 Selling,
General and Administrative expenses decreased by $135,219 to $1,195,408 in 2023 from $1,330,627 in 2022. Included within Selling,
General and Administrative Expenses are non-cash charges for stock-based compensation as the result of amortizing employee and
non-employee shares and options which have been issued by the Company over various periods. The charge for 2023 was $10,141, a
decrease of $175,469 from $185,610 in 2022, following an amendment to the Fountainhead Consulting Agreement. Also included within
Selling, General and Administrative Expenses are Sales Commissions, which increased by $56,836 to $269,746 reflecting an increased
level of sales in the US.

 The
remaining Selling, General and Administrative expenses decreased by $16,585 from $932,106 to $915,521. Patent costs decreased by $21,186
due to lower costs of NovaVision patents. Marketing costs decreased by $14,897 reflecting the launch of the VBAS AC product in 2022;
this was offset by higher insurance costs of $11,009 and net other cost increases of $8,489.

 Interest
Expense:

 Interest
comprises expense on the Company's debt and insurance policy financing. Related Party Interest expense for 2023 increased $9,952
following the issuance of related party notes during 2022 to $49,515 from $39,563 for 2022. Other Interest expense for 2023 increased
by $886 to $53,550 from $52,664 for 2022.

loss from Discontinued Operations:

loss from Discontinued Operations increased by $1,399 to $6,611 in 2023 from $5,212 in 2022 as the business is wound down.

 Liquidity
and Capital Resources

 Liquidity

 The
following table shows cash flow and liquidity data for the years ended December 31, 2023 and December 31, 2022:

 2023

 2022

 $ Change

 Cash

 $
 57,291

 $
 37,035

 $
 20,256

 Accounts receivable, inventory and other current assets

 $
 526,799

 $
 480,728

 $
 46,071

 Total current liabilities

 $
 (4,074,487
)

 $
 (3,654,796
)

 $
 (419,691
)

 Working capital

 $
 (3,490,397
)

 $
 (3,137,033
)

 $
 (353,364
)

 Cash provided by financing activities

 $

 $
 165,889

 $
 (165,678
)

Activities. Cash provided by (used in) operating activities comprises net loss adjusted for non-cash items and the effect of changes
in working capital and other activities. The net repayment of normal insurance financing should also be taken into account when considering
cash provided by (used in) operating activities.

 The
following table shows the principal components of cash provided by (used in) operating activities during the years ended December 31,
2023 and 2022, with a commentary of changes during the years and known or anticipated changes:

 2023

 2022

 $ Change

 Net loss

 $
 (69,691
)

 $
 (404,917
)

 $
 335,226

 Adjustments to reconcile net loss to cash used in operating activities:

 Amortization and depreciation of assets

 $
 60,752

 $
 61,403

 $
 (651
)

 Stock based compensation

 $
 10,141

 $
 185,610

 $
 (175,469
)

 Other

 -

 $
 15,515

 $
 (15,515
)

 $
 70,893

 $
 262,528

 $
 (191,635
)

 Net loss adjusted for non-cash items

 $
 1,202

 $
 (142,389
)

 $
 143,591

 Changes in working capital

 Accounts receivable

 $
 (59,027
)

 $
 (30,108
)

 $
 (28,919
)

 Accounts payable and accrued liabilities

 $
 (21,779
)

 $
 (63,283
)

 $
 41,504

 Inventory

 $
 14,729

 $
 (56,868
)

 $
 71,597

 Prepaid expenses and net insurance financing repayments

 $
 (3,771
)

 $
 (21,547
)

 $
 17,776

 Accrued interest (not paid in cash)

 $
 97,515

 $
 92,227

 $
 5,288

 Changes in discontinued operations, net

 $

 $
 (1,659
)

 $
 2,431

 $
 28,439

 $
 (81,238
)

 $
 109,677

 The
adjustments to reconcile net income (loss) to cash of $1,202 in the period have no impact on liquidity, and the change in net income
(loss) of $143,591 is due to the increase in Vycor sales, as is the change in accounts receivable of $(28,919).

 Additional
inventory of $104,160 was purchased during the year ended December 31, 2023 as part of normal production, and the Company anticipates
purchasing additional new inventory of approximately $150,000 during the next twelve months.

 Investing
Activities. Cash used in investing activities of continuing operations for the year ended December 31, 2023 was $9,386 compared to
$2,780 in 2022.

 `

 Financing
Activities. During the years ended December 31, 2023 and 2022 the Company received funds of $0 and $172,500, respectively, in respect of loans
from Fountainhead.

 Liquidity
and Plan of Operations, Ability to Continue as a Going Concern

 The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company
has incurred losses since its inception, including a net loss available to common stockholders of $69,691 and $404,917 for the years
ending December 31, 2023 and 2022 respectively and has not generated sufficient cash flows from operations although did generate positive
cash flows from operations for the year ended December 31, 2023. As at December 31, 2023 the Company had a working capital deficiency
of $3,490,397, which includes related party liabilities of $2,959,485. As a result these conditions, among others, raise substantial doubt regarding
our ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from
the outcome of this uncertainty.

 As
described earlier in this ITEM 1 " Strategy ", the Company is executing on a plan to achieve a reduction in cash operating
losses. Included within the working capital deficiency above is a term note for $300,000 to EuroAmerican Investment Corp. ("EuroAmerican"),
together with accrued interest of $472,897, which has a maturity date of March 31, 2025, having been extended on a number of occasions
from its initial due date of June 11, 2011. At this time, it is not known whether any further extension of the note beyond March 31,
2025 will be available. However, the Company believes it may not have sufficient cash to meet its various cash needs through March 31,
2025 unless the Company is able to obtain additional cash from the issuance of debt or equity securities. Fountainhead, the Company's
largest shareholder, has provided working capital funding to the Company on an as-needed basis, although there is no guarantee that this
will continue to be the case. The Company may consider seeking additional equity or debt funding, although there is no assurance that
this would be available on acceptable terms or at all. If adequate funds are not available, the Company may have to delay or curtail
development or commercialization of products or cease some of its operations.

 Off-Balance
Sheet Arrangements

 As
of December 31, 2023, we had no off-balance sheet arrangements.

 Seasonality

 Our
operating results are not affected by seasonality.

 Inflation

 Our
business and operating results are not affected in any material way by inflation, although rising raw material and labor costs will result
in an increase in the cost of sales.

 Critical
Accounting Estimates

 Uses
of estimates in the preparation of financial statements

 The
preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make
estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results
could differ from those estimated. To the extent management's estimates prove to be incorrect, financial results for future periods
may be adversely affected. Significant estimates and assumptions contained in the accompanying consolidated financial statements include
management's estimate of the allowance for uncollectible accounts receivable, provision for inventory obsolescence, useful life
of intangible assets, and the fair values of options and warrant included in the determination of debt discounts and stock-based compensation.

 Contractual
Obligations

 As
a "smaller reporting company" as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 As
a "smaller reporting company" as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

 Set
forth below are the audited consolidated financial statements for the Company for the fiscal years ended December 31, 2023 and 2022 and
the report thereon of Prager Metis CPAs, LLC (PCAOB ID No. 273),

 REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 To
the Board of Directors and Stockholders of

 Vycor
Medical, Inc.

 Opinion
on the Financial Statements

 We
have audited the accompanying consolidated balance sheets of Vycor Medical, Inc. ("the Company") as of December 31, 2023
and 2022, and the related consolidated statements of comprehensive loss, stockholders' deficiency, and cash flows for the years
ended December 31, 2023 and 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the
results of its operations and its cash flows for the years ended December 31, 2023 and 2022, in conformity with accounting principles
generally accepted in the United States of America.

 Going
Concern

 The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
1 to the financial statements, the Company has incurred net losses since inception, including a net loss of $69,691 and $404,917 for
the years ended December 31, 2023 and 2022 respectively, and has not generated sufficient cash flows from its operations. As of December
31, 2023, the Company had a working capital deficiency of $3,490,397, which includes related party liabilities of $2,959,485. These factors,
among others, raise substantial doubt regarding the Company's ability to continue as a going concern. Management's plans
in regard to these matters are described in Note 1 to the financial statements. The accompanying financial statements do not include
any adjustments that might result from the outcome of this uncertainty.

 Basis
for Opinion

 These
financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.

 Critical
Audit Matters

 The
critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required
to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements
and (2) involved our especially challenging, subjective or complex judgments. We determined that there are no critical audit matters
for the current audit period.

 /s/
 Prager Metis CPAs, LLC

 We
 have served as the Company's auditor since 2018.

 Hackensack,
 New Jersey

 VYCOR

 Consolidated
Balance Sheets

 2023

 2022

 ASSETS

 Current Assets

 Cash

 $
 57,291

 $
 37,035

 Trade accounts receivable

 215,231

 156,204

 Inventory

 234,145

 248,874

 Prepaid expenses and other current assets

 76,684

 74,438

 Current assets of discontinued operations

 1,212

 Total Current Assets

 584,090

 517,763

 Fixed assets, net

 252,404

 303,770

 Intangible and Other assets:

 Security deposits

 6,000

 6,000

 Operating lease–- right of use assets

 149,804

 32,645

 Total Intangible and Other assets

 155,804

 38,645

 TOTAL ASSETS

 $
 992,298

 $
 860,178

 LIABILITIES AND STOCKHOLDERS' DEFICIENCY

 Current Liabilities

 Accounts payable

 $
 117,801

 $
 200,044

 Accrued interest: Other

 472,897

 424,897

 Accrued interest: Related party

 195,522

 146,007

 Accrued interest

 195,522

 146,007

 Accrued liabilities–- Other

 151,816

 91,352

 Accrued liabilities–- Related Party

 2,270,590

 1,946,220

 Accrued liabilities

 2,270,590

 1,946,220

 Notes payable: Other

 328,267

 324,711

 Notes payable: Related Party

 Notes payable

 Current operating lease liabilities

 45,321

 29,591

 Current liabilities of discontinued operations

 ( 1,100
)

 ( 1,399
)

 Total Current Liabilities

 4,074,487

 3,654,796

 Operating lease liability – long term

 100,379

 -

 Loan Payable–- SBA EIDL

 142,908

 146,253

 Total Liabilities

 4,317,774

 3,801,049

 STOCKHOLDERS' DEFICIENCY

 Preferred stock, $ 0.0001
 par value, 10,000,000 shares
authorized:

 Preferred C Stock, 1 and 1 share issued and outstanding as at December
31, 2023 and December 31, 2022 respectively

 -

 -

 Preferred D Stock, 270,306 and 270,306 shares issued and outstanding as
at December 31, 2023 and December 31, 2022 respectively

 Preferred Stock, value

 Common Stock, $ 0.0001 par value, 55,000,000 shares authorized at December 31, 2023 and December 31, 2022, 32,732,169 and 32,630,506 shares issued and 32,628,835 and 32,527,172 outstanding at December 31, 2023 and December 31, 2022 respectively

 3,273

 3,263

 Additional Paid-in Capital

 29,365,070

 29,355,626

 Treasury Stock ( 103,334 shares of Common Stock as at December 31, 2023 and December 31, 2022 respectively, at cost)

 ( 1,033
)

 ( 1,033
)

 Accumulated Deficit

 ( 32,820,490
)

 ( 32,426,429
)

 Accumulated Other Comprehensive Income (Loss)

 127,677

 127,675

 Total Stockholders' Deficiency

 ( 3,325,476
)

 ( 2,940,871
)

 TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY

 $
 992,298

 $
 860,178

 See
accompanying notes to consolidated financial statements

 VYCOR

 Consolidated
Statements of Comprehensive Loss

 2023

 2022

 For the year ended December 31,

 2023

 2022

 $
 1,460,604

 $
 1,222,989

 Cost of Goods Sold

 144,950

 140,644

 1,315,654

 1,082,345

 Operating Expenses:

 Research and development

 22,558

 -

 Depreciation and amortization

 57,497

 58,232

 Selling, general and administrative

 1,195,408

 1,330,627

 Total Operating Expenses

 1,275,463

 1,388,859

 Operating income (loss)

 40,191

 ( 306,514
)

 Other Income (Expense)

 Interest expense: Related Party

 ( 49,515
)

 ( 39,563
)

 Interest expense: Other

 ( 53,550
)

 ( 52,664
)

 Interest expense

 ( 53,550
)

 ( 52,664
)

 Loss on foreign currency exchange

 ( 206
)

 ( 964
)

 Total Other Income (Expense)

 ( 103,271
)

 ( 93,191
)

 Loss Before Provision for Income Taxes

 ( 63,080
)

 ( 399,705
)

 Provision for income taxes

 -

 -

 Net Loss from continuing operations

 ( 63,080
)

 ( 399,705
)

 Loss from discontinued operations

 ( 6,611
)

 ( 5,212
)

 Net Loss

 ( 69,691
)

 ( 404,917
)

 Preferred stock dividends

 ( 324,370
)

 ( 324,370
)

 Net Loss Available to Common Stockholders

 $
)

 $
 ( 729,287
)

 Other Comprehensive Income (Loss)

 Foreign Currency Translation Adjustment

 Comprehensive Loss

 $
 ( 69,689
)

 $
 ( 404,916
)

 Net Loss Per Share–- basic and diluted

 Net Loss from continuing operations

 $
 ( 0.00
)

 $
 ( 0.01
)

 Loss from discontinued operations

 $
 ( 0.00
)

 $
 ( 0.00
)

 Net Loss available to common stockholders

 $
 ( 0.01
)

 $
 ( 0.02
)

 Weighted Average Number of Shares Outstanding – Basic and Diluted

 32,603,767

 31,708,076

 See
accompanying notes to consolidated financial statements

 VYCOR

 Consolidated
Statement of Stockholders' Deficiency

 Paid-in Capital

 Accumulated Deficit

 OCI (Loss)

 Total

 Common Stock

 Preferred C

 Preferred D

 Treasury Stock

 Additional

 Accum

 Paid-in Capital

 Accumulated Deficit

 OCI (Loss)

 Total

 Accumulated Comprehensive Loss

 30,921,701

 $
 3,092

 $

 $

)

 ($
 1,033
)

 $
 29,172,169

 ($
 31,697,142
)

 $
 127,674

 ($
 2,395,213
)

 Issuance of stock for board and consulting fees

 1,708,805

 -

 -

 -

 -

 -

 183,457

 183,628

 Comprehensive Income

 Net loss for year ended December 31, 2022

 ( 729,287
)

 ( 729,287
)

 Balance at December 31, 2022

 32,630,506

 3,263

)

 ( 1,033
)

 29,355,626

 ( 32,426,429
)

 127,675

 ( 2,940,871
)

 Balance

 32,630,506

 3,263

)

 ( 1,033
)

 29,355,626

 ( 32,426,429
)

 127,675

 ( 2,940,871
)

 Issuance of stock for board and consulting fees

 101,663

 -

 -

 -

 -

 -

 9,444

 9,454

 Comprehensive Income

 Net loss for year ended December 31, 2023

)

)

 Net loss for period

)

)

 Balance at December 31, 2023

 32,732,169

 $
 3,273

 $

 $

)

 ($
 1,033
)

 $
 29,365,070

 ($
 32,820,490
)

 $
 127,677

 ( 3,325,476
)

 Balance

 32,732,169

 $
 3,273

 $

 $

)

 ($
 1,033
)

 $
 29,365,070

 ($
 32,820,490
)

 $
 127,677

 ( 3,325,476
)

 See
accompanying notes to consolidated financial statements

 VYCOR

 Consolidated
Statements of Cash Flows

 2023

 2022

 For the twelve months ended

 2023

 2022

 Cash flows from operating activities:

 Net loss

 $
 ( 69,691
)

 $
 ( 404,917
)

 Adjustments to reconcile net loss to cash provided by (used in) operating activities:

 Depreciation of fixed assets

 60,752

 61,403

 Inventory provision

 -

 15,515

 Stock based compensation

 10,141

 185,610

 Changes in assets and liabilities:

 Accounts receivable

 ( 59,027
)

 ( 30,108
)

 Inventory

 14,729

 ( 56,868
)

 Prepaid expenses

 ( 3,982
)

 ( 14,936
)

 Accrued interest–- Related Party

 49,515

 39,563

 Accrued interest–- Other

 48,000

 52,664

 Accounts payable

 ( 82,243
)

 ( 27,676
)

 Accrued liabilities–- Other

 60,464

 ( 35,607
)

 Changes in discontinued operations, net

 ( 1,659
)

 Cash provided by (used in) operating activities

 29,430

 ( 217,016
)

 Cash flows from investing activities:

 Purchase of fixed assets

 ( 9,386
)

 ( 2,780
)

 Cash used in investing activities

 ( 9,386
)

 ( 2,780
)

 Cash flows from financing activities:

 Proceeds from Notes Payable–- Related Party

 -

 172,500

 Proceeds – Notes Payable - Other

 63,122

 56,249

 Repayments - Notes Payable - Other

 ( 62,911

)

 ( 62,860
)

 Cash provided by financing activities

 165,889

 Effect of exchange rate changes on cash

 Net increase (decrease) in cash

 20,256

 ( 53,906
)

 Cash at beginning of year

 37,035

 90,941

 Cash at end of year

 $
 57,291

 $
 37,035

 Supplemental Disclosures of Cash Flow information:

 Cash paid for interest

 $
 5,550

 $
 8,246

 Cash paid for income tax

 $

 $

 Non-cash activities:

 Unamortized stock compensation

 $
 2,364

 $
 3,050

 See
accompanying notes to consolidated financial statements

 VYCOR

 Notes
to Consolidated Financial Statements

 1.
 BUSINESS OF THE COMPANY AND GOING CONCERN

 Business
Description

 Vycor
Medical, Inc. (the "Company") designs, develops and markets neurological medical devices and therapies through two operating
divisions: Vycor Medical and NovaVision. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and
medical professionals; NovaVision focuses on neuro-stimulation therapies and diagnostic devices for the treatment and screening of vision
field loss resulting from neurological damage.

 Ability
to continue as a Going Concern

 The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company
has incurred losses since its inception, including a net loss of $ 69,691
 and $ 404,917
 for the years ending December 31, 2023 and 2022
respectively and has not generated sufficient cash flows from operations. As at December 31, 2023 the Company had a working capital deficiency
of $ 3,490,397,
which includes related party liabilities of $ 2,959,485.
As a result these conditions, among others, raise substantial doubt regarding our ability to continue as a going concern. The consolidated
financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of
assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty

 The
Company is executing on a plan to achieve a reduction in cash operating losses. Included within the working capital deficiency above
is a term note for $ 300,000 to EuroAmerican Investment Corp. ("EuroAmerican"), together with accrued interest of $ 472,897,
which has a maturity date of March 31, 2025, having been extended on a number of occasions from its initial due date of June 11, 2011. At this
time, it is not known whether any further extension of the note beyond March 31, 2025 will be available. However, the Company believes it may
not have sufficient cash to meet its various cash needs through March 31, 2025 unless the Company is able to obtain additional cash from
the issuance of debt or equity securities. Fountainhead, the Company's largest shareholder, has provided working capital funding
to the Company on an as-needed basis, although there is no guarantee that this will continue to be the case. The Company may consider
seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all.
If adequate funds are not available, the Company may have to delay or curtail development or commercialization of products or cease some
of its operations.

 2.
 SIGNIFICANT ACCOUNTING POLICIES

 Principles
of Consolidation and Basis of Presentation

 The
consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a
Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries
of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and balances have
been eliminated in consolidation. Following the decision in April 2020 to close the German office of NovaVision, the activities of NovaVision
GmbH have been accounted for as discontinued operations.

Recognition

 On
January 1, 2018, the Company adopted ASC 606, Revenue from Contracts with Customers and all the related amendments (new revenue standard)
to all contracts.

 Vycor
Medical generates revenue from the sale of its surgical access system to hospitals and other medical professionals. Vycor Medical records
revenue from product sales when obligations under the terms of a contract with customers are satisfied. Generally, this occurs with the
transfer of control of the goods to customers. Vycor Medical does not provide for product returns or warranty costs.

 Vycor
determines revenue recognition through the following steps:

 Identification
 of the contract, or contracts, with a customer

 Identification
 of the performance obligations in the contract

 Determination
 of the transaction price

 Allocation
 of the transaction price to the performance obligations in the contract

 Recognition
 of revenue when Vycor satisfy a performance obligation

generates revenues from various programs, therapy services and other sources such as software license sales. Therapy services revenues
represent fees from NovaVision's vision restoration therapy software, eye movement training software, diagnostic software, clinic
set up and training fees, and the professional and support services associated with the therapy. NovaVision provides vision restoration
therapy directly to patients. The typical therapy program consists of NeuroEyeCoach, performed over 2-4 weeks, and six modules of Vision
Restoration Therapy, performed over 6 months. A patient contract comprises set-up fees and monthly therapy fees. Set-up fees are recognized
at the outset of the contract and therapy revenue is recognized ratably over the therapy period. Patient therapy is restricted to being
completed by a patient within a specified time frame.

 Deferred
revenue results from patients paying for the therapy in advance of receiving the therapy.

 As
part of the adoption of ASC 606, see Note 7 to the Consolidated Financial Statements for further disaggregation of revenue.

 Reclassifications

 Certain
prior period amounts have been reclassified to conform with the current period presentation; on the cash flow statement, proceeds from and repayments of insurance
financing has been separated out rather than being netted off.

 Cash
and cash equivalents

 The
Company maintains cash balances at various financial institutions. Accounts at each institution in the U.S. are insured by the Federal
Deposit Insurance Corporation up to $ 250,000. Cash balances may at times exceed the FDIC insured limits. The Company considers all highly
liquid investments with a maturity of three months or less when purchased to be cash equivalents. Included within cash are deposits paid
by patients, held by the Company until the patient returns the chinrest at the end of therapy. At December 31, 2023 and
2022 patient deposits amounted to $ 20,951 and $ 19,154, respectively, and are included in Accrued Liabilities.

 Accounts
Receivable and Allowance for Doubtful Accounts Receivable

 The
Company's accounts receivable are due from the hospitals and distributors in the case of Vycor Medical, and from patients directly
for therapy or physicians for diagnostic products in the case of NovaVision. Accounts receivable are due once products have been delivered
or at the time the therapy is initiated; however, for NovaVision therapy patients sometimes credit is extended through various payment
plans based on individual financial conditions, generally not to exceed the therapy period. The outstanding balances are stated net of
an allowance for doubtful accounts.

 We
have a policy of reserving for uncollectible accounts based on our best estimate of the amount of probable credit losses in our existing
accounts receivable. We extend credit to our customers based on an evaluation of their financial condition and other factors. We generally
do not require collateral or other security to support accounts receivable. We perform ongoing credit evaluations of our customers and
maintain an allowance for potential bad debts if required. We determine whether an allowance for doubtful accounts is required by evaluating
specific accounts where information indicates the customers may have an inability to meet financial obligations. In these cases, we use
assumptions and judgment, based on the best available facts and circumstances, to record a specific allowance for those customers against
amounts due to reduce the receivable to the amount expected to be collected. These specific allowances are re-evaluated and adjusted
as additional information is received. The amounts calculated are analyzed to determine the total amount of the allowance. We may also
record a general allowance as necessary. Direct write-offs are taken in the period when we have exhausted our efforts to collect overdue
and unpaid receivables or otherwise evaluate other circumstances that indicate that we should abandon such efforts.

 Inventories

 Inventories
consist of raw materials, work in process and finished goods that are stated at the lower of cost determined using the weighted average
cost method, or net realizable value. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated
costs to complete and dispose of the product. If the Company identifies excess, obsolete or unsalable items, its inventories are written
down to their realizable value in the period in which the impairment is first identified. The charge provision for inventory obsolescence
for the years ended December 31, 2023 and 2022 was $ 168 and $ 13,160, respectively. Shipping and handling costs incurred for inventory
purchases and product shipments are recorded in cost of sales in the Company's consolidated statements of comprehensive loss.

 Leases

 The
Company has one leased building in Boca Raton, Florida that is classified as operating lease right-of use ("ROU") assets
and operating lease liabilities in the Company's consolidated balance sheet as per ASC 842. ROU assets and lease liabilities are
recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding
12 months. Minimum lease payments include only the fixed lease component of the agreement. Operating lease expense is recognized on a
straight-line basis over the lease term and is included in cost of Selling, General and Administrative expenses.

 The
standard was effective for us beginning January 1, 2019. The Company elected the available practical expedients on adoption. The adoption
had a material impact on our consolidated balance sheets but did not have a material impact on our consolidated statements of comprehensive
loss. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

 Discontinued
Operations

 In
accordance with ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, a disposal
of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal
represents a strategic shift that has (or will have) a major effect on an entity's operations and financial results when the components
of an entity meets the criteria in paragraph 205-20-45-1E to be classified as held for sale. When all of the criteria to be classified
as held for sale are met, including management, having the authority to approve the action, commits to a plan to sell the entity, the
major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and
liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations (which
we presented as operations to be disposed and operations disposed), less applicable income taxes (benefit), shall be reported as components
of net income (loss) separate from the net income (loss) of continuing operations in accordance with ASC 205-20-45.

 Foreign
Currency

 The
Euro is the local currency of the country in which the discontinued operations of NovaVision GmbH conducts its operations and is considered
the functional currency of this entity; the GB Pound is the local currency of the country in which Sight Science Limited conducts its
operations and is considered the functional currency of this entity. All balance sheet amounts are translated to U.S. dollars using the
U.S. exchange rate at the balance sheet date except for the equity section which is translated at historical rates. Operating statement
amounts are translated using an average exchange rate for the period of operations. Foreign currency translation effects are accumulated
as part of the accumulated other comprehensive income (loss) and included in stockholders' deficiency in the accompanying Consolidated
Balance Sheets.

 Educational
marketing and advertising expenses

 The
Company may incur costs for the education of customers on the uses and benefits of its products. The Company will include education,
marketing and advertising expense as a component of selling, general and administrative costs as such costs are incurred. There were
no such expenses for the years ended December 31, 2023 and 2022.

 Income
taxes

 We
use the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, "Income Taxes." Under
this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred
tax consequences of temporary differences resulting from matters that have been recognized in an entity's financial statements
or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance
is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is
more likely than not some portion or all of the deferred tax assets will not be realized.

 ASC
Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and
prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position
taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties,
accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for any of the reporting periods
presented.

 Fixed
assets

 Fixed
assets are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives
of the assets. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

 Patents
and Other Intangible Assets

 The
Company capitalizes legal and related costs associated with the establishment and enhancement of patents for its products once patents
have been applied for. Costs associated with the development of the patented item or processes are charged to research and development
costs as incurred. The capitalized costs are amortized over the life of the patent. The Company reviews intangible assets on an annual
in accordance with the authoritative guidance. Trademarks have an indefinite life and are reviewed annually by management for impairment
in accordance with the authoritative guidance.

 Impairment
of long-lived assets

 Long-lived
assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable. For assets that
are to be held and used, impairment is recognized when the estimated undiscounted cash flows associated with the asset or group of assets
is less than their carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss
is recorded as the difference between the carrying value and fair value. Fair values are determined based on quoted market values, discounted
cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the lower of carrying value or
estimated net realizable value.

 Research
and Development

 The
Company expenses all research and development costs as incurred. For the years ended December 31, 2023 and 2022, the amounts charged
to research and development expenses were $ 22,558 and $ 0, respectively.

 Software
Development Costs

 The
Company accounts for software development costs in accordance with ASC 350-40, whereby all costs incurred during the preliminary stage
of a development project should be charged to expense as incurred. Capitalization of costs begins after the preliminary stage has been
completed, management commits to funding the project, it is probable that the project will be completed, and the software will be used
for its intended function. All post-implementation costs are charged to expense as incurred. Accordingly, direct internal and external
costs associated with the development of the features and functionality of the Company's software, incurred during the application
development stage, are capitalized and amortized using the straight-line method of the estimated life of five years. There was no capitalized
for software development during the years ended December 31, 2023 and 2022.

 Uses
of estimates in the preparation of financial statements

 The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimated.
To the extent management's estimates prove to be incorrect, financial results for future periods may be adversely affected. Significant
estimates and assumptions contained in the accompanying consolidated financial statements include management's estimate of the
allowance for uncollectible accounts receivable and provision for inventory obsolescence.

 Stock
Compensation

 The
Company recognizes the cost of all stock -based payments under the relevant authoritative accounting guidance. Stock-based payments include
any remuneration paid by the Company in shares of the Company's common stock or financial instruments that grant the recipient
the right to acquire shares of the Company's common stock. For stock-based payments to employees, which consist only of awards
made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic
718, "Stock Compensation". Stock-based payments to consultants, service providers and other non-employees are accounted for
in accordance with ASC Topic 718, ASC Topic 505, "Equity Payments to Non-Employees" or other applicable authoritative guidance.

 Convertible
Instruments

 We
evaluate and account for conversion options embedded in convertible instruments in accordance with ASC 815 "Derivatives and Hedging
Activities".

 Applicable
GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative
financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and
risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host
contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at
fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same
terms as the embedded derivative instrument would be considered a derivative instrument.

 We
account for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their
host instruments) as follows: We record when necessary, discounts to convertible notes for the intrinsic value of conversion options
embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date
of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized
over the term of the related debt to their stated date of redemption. The embedded conversion option in connection with our convertible
debt could not be exercised unless and until we completed a Qualifying Financing transaction. Accordingly, we determined based on authoritative
guidance that the embedded conversion option is deemed to be a contingent conversion rather than active conversion option that did not
require accounting recognition at the commitment dates of the issuances of the Notes.

 Fair
Value Measurements

 We
adopted the provisions of ASC Topic 820, "Fair Value Measurements and Disclosures", which defines fair value as used in numerous
accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 The
estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and
accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these
instruments. The carrying amounts of our short and long-term credit obligations approximate fair value because the effective yields on
these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants
and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

 ASC
820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 Level
1 — quoted prices in active markets for identical assets or liabilities

 Level
2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

 Level
3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 The
Company has no financial instruments measured at fair value on a recurring basis.

 Net
Loss Per Share

 Basic
net income (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted-average number
of common shares outstanding during the period. Diluted net income (loss) per share is computed giving effect to all dilutive potential
common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise
of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when
the effect would be to reduce a net loss per share.

 The
following table sets forth the potential shares of common stock that are included in the calculation of diluted net income per share
where a net income is reported:

 SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE

 2023

 2022

 Debentures convertible into common stock

 3,680,460

 3,451,889

 Preferred shares convertible into common stock

 1,272,052

 1,272,052

 Total

 4,952,512

 4,723,941

 Anti-dilutive shares

 4,952,512

 4,723,941

 Recent
Accounting Pronouncements

 From
time-to-time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that
may have an impact on the Company's accounting and reporting. The FASB issued Accounting Standards Update (ASU) 2023-07 in November 2023, to be effective for fiscal years
beginning after December 15, 2023. The ASU is to improve reportable segment disclosures. Management has assessed the ASU and has concluded
that it will not have an impact on its accounting or reporting when implemented, as the additional disclosure effects items that are not
applied at a segment level. The Company believes that other recently issued accounting pronouncements
and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting
or that such impact will not be material to its financial position, results of operations and cash flows when implemented.

 3.
 DISCONTINUED OPERATIONS

 In
April 2020, the board of Vycor took the decision to close the German operations of NovaVision, including the German office and NovaVision
GmbH, and instead migrate to a licensed business model; effective July 1, 2020, Vycor entered into a license agreement with a German-based
partner. The NovaVision German office was closed effective June 30, 2020. The Company will continue to fund the remaining expenses of
the German operations, which are non-material, until such a time as NovaVision GmbH will be formally wound up.

 Reconciliation
of the major line items from discontinued operations that are presented in the consolidated balance sheets and consolidated statements
of comprehensive loss are as follows:

 SCHEDULE OF DISCONTINUED OPERATIONS

 Major
line items constituting assets and liabilities in the consolidated balance sheets:

 2023

 2022

 ASSETS

 Current Assets

 Cash

 $

 $
 1,212

 Total Current Assets

 1,212

 TOTAL ASSETS

 $

 $
 1,212

 LIABILITIES

 Current Liabilities

 Accounts payable

 $

 $

 Other current liabilities

 ( 1,104
)

 ( 2,092
)

 Total Current Liabilities

 $
 ( 1,100
)

 $
 ( 1,399
)

 Major
line items constituting loss from discontinued operations

 2023

 2022

 For the years

 ended December 31,

 2023

 2022

 $
 -

 $
 -

 Cost of Goods Sold

 -

 -

 -

 -

 Operating Expenses:

 Selling, general and administrative

 6,379

 5,062

 Total Operating Expenses

 6,379

 5,062

 Operating Loss

 ( 6,379
)

 ( 5,062
)

 Other Income (Expense)

 Loss on foreign currency exchange

 ( 232
)

 ( 150
)

 Total Other Income (Expense)

 ( 232
)

 ( 150
)

 Loss Before Provision for Income Taxes

 ( 6,611
)

 ( 5,212
)

 Provision for income taxes

 -

 -

 Loss from discontinued operations, net of tax

 $
 ( 6,611
)

 $
 ( 5,212
)

 4.
 INVENTORY

 SCHEDULE OF INVENTORY

 2023

 2022

 Raw materials and work in process

 $
 88,236

 $
 109,894

 Finished goods

 145,909

 138,980

 Total Inventory

 $
 234,145

 $
 248,874

 5.
 LEASE

 The
Company recognized the following related to a lease in its consolidated balance sheets:

 SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES

 2023

 2022

 Operating Lease ROU Assets

 $
 149,804

 $
 32,645

 Operating Lease Liabilities

 Current portion

 $
 45,321

 $
 29,591

 Long-term portion

 100,379

 -

 Lease Liabilities

 $
 145,700

 $
 29,591

 6.
 NOTES PAYABLE

 Related
Party Notes Payable consists of:

 SUMMARY OF NOTES PAYABLE

 2023

 2022

 On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $ 30,000. The notes bear interest at 10 % per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. The note was extended for another twelve months on its due date to June 25, 2024 or on demand by the Payee.

 $
 30,000

 $
 30,000

 Between March 26, 2018 and November 17, 2022 the Company issued fifteen promissory notes to Fountainhead Capital Management Limited for $ 463,373. The notes bear interest at 10 % per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. All of the notes have been extended on their due dates for another twelve months. The Notes will be due between April 2024 and March 2025 or on demand by the Payee.

 463,373

 463,373

 Total Related Party Notes Payable

 $

 $

 Other
Notes Payable consists of:

 2023

 2022

 On March 25, 2011 the Company issued a term note for $ 300,000 to EuroAmerican Investment Corp. ("EuroAmerican"). The term note bears interest at 16 % per annum and was due June 25, 2011, and has been extended on a number of occasions. On the note's most recent due date, the note was amended and extended to March 31, 2025. See further note below.

 $
 300,000

 $
 300,000

 Insurance policy finance agreements and current portion of EIDL Loan (see Long-Term Notes Payable below)

 28,267

 24,711

 Total Notes Payable:

 $
 328,267

 $
 324,711

 Long-Term
Notes Payable consists of:

 2023

 2022

 On July 7, 2020, the Company was granted a $ 150,000 loan under the Economic Injury Disaster Loan Program pursuant to the Coronavirus Aid, Relief and Economic Security (CARES) Act ("Loan"). The Loan, evidenced by a promissory note dated July 7, 2020, has a term of thirty ( 30) years, bears interest at a fixed rate of three and three-quarters percent ( 3.75 %) per annum, with monthly payments in the amount of $ 731.00 per month commencing July 7, 2021 and is secured by essentially all of the assets of the Company. The proceeds of the Loan have been used for general working capital purposes to alleviate economic injury caused by disaster occurring in the month of January 2020 and continuing thereafter.

 $
 142,908

 $
 146,253

 Total Long-term Notes Payable:

 $
 142,908

 $
 146,253

 On
January 24, 2018 the Company entered into an amendment agreement (the "Amendment") with EuroAmerican Investments ("EuroAmerican")
regarding its $ 300,000 loan note (the "Note"). Under the Amendment, the Note was extended and the conversion terms of the
Note reduced to $ 0.21, the same as the offering price of the 2018 Offering. Conversion of the Note and accrued interest would result
in the issuance of 3,680,462 shares of Common Stock. Notwithstanding, EuroAmerican agreed that the Note could not be converted without
first offering the Company the right to redeem the Note at principal and accrued interest, and secondly Fountainhead the right to purchase
the Note, which cannot be converted prior to such offer and the failure of the Company and Fountainhead to exercise such option in accordance
with the amendment terms. The amendment was recognized as a modification, based on the guidance in ASC 470-50. No other term was amended
on the Note.

 The
Company routinely finances all their insurance policies through a third-party finance company which requires a down payment and subsequent
monthly payments, the time periods vary from 10 months to 12 equal monthly payments.

 7.
 SEGMENT REPORTING, GEOGRAPHICAL INFORMATION

 (a)
Business segments

 The
Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on
neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss. Discontinued operations were
part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets
for each segment.

 SCHEDULE OF BUSINESS SEGMENTS INFORMATION

 2023

 2022

 Year Ended December 31,

 2023

 2022

 Revenue:

 Vycor Medical

 $
 1,378,598

 $
 1,130,915

 $
 82,006

 $
 92,074

 $
 1,460,604

 $
 1,222,989

 Vycor Medical

 $
 1,238,878

 $
 997,667

 $
 76,776

 $
 84,678

 $
 1,315,654

 $
 1,082,345

 Operating Income (Loss)

 Vycor Medical

 $
 383,847

 $
 239,327

 $
 ( 191,810
)

 $
 ( 223,351
)

 Corporate

 $
 ( 151,846
)

 $
 ( 322,490
)

 Income (Loss)

 $
 40,191

 $
 ( 306,514
)

 2023

 2022

 Total Assets:

 Vycor Medical

 $
 957,936

 $
 822,174

 33,623

 36,792

 Discontinued operations

 1,212

 Total Assets

 $
 992,298

 $
 860,178

 (b)
Geographic segments.

 The
Company operates in two geographic segments, the United States and Europe. Discontinued operations were part of NovaVision and revenues
and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment.

 SUMMARY OF GEOGRAPHIC INFORMATION

 2023

 2022

 Year Ended December 31,

 2023

 2022

 Revenue:

 United States

 $
 1,453,895

 $
 1,214,723

 Europe

 $
 6,709

 $
 8,266

 $
 1,460,604

 $
 1,222,989

 United States

 $
 1,308,984

 $
 1,074,143

 Europe

 $
 6,670

 $
 8,202

 $
 1,315,654

 $
 1,082,345

 Operating Income (Loss)

 United States

 $
 60,484

 $
 ( 289,439
)

 Europe

 $
 ( 20,293
)

 $
 ( 17,075
)

 Income (Loss)

 $
 40,191

 $
 ( 306,514
)

 2023

 2022

 Total Assets:

 United States

 $
 985,718

 $
 854,236

 Europe

 5,841

 4,730

 Discontinued operations

 1,212

 Total Assets

 $
 992,298

 $
 860,178

 8.
 FIXED ASSETS

 Fixed
Assets and the estimated lives used in the computation of depreciation are as follows:

 SCHEDULE OF FIXED ASSETS

 Estimated

 Useful Lives

 2023

 2022

 Machinery and equipment

 3 years

 $
 70,832

 $
 64,762

 Leasehold Improvements

 3 years

 8,881

 8,881

 Purchased Software

 3 years

 27,706

 27,706

 Molds and Tooling

 5 years

 808,611

 808,611

 Furniture and fixtures

 7 years

 11,152

 11,152

 Therapy Devices

 3 years

 107,943

 104,627

 Internally Developed Software

 5 years

 363,472

 363,472

 Property, and Equipment, Gross

 1,398,597

 1,389,211

 Less: Accumulated depreciation and amortization

 ( 1,146,193
)

 ( 1,085,441
)

 Property and Equipment, net

 252,404

 303,770

 Depreciation
expense for the years ended December 31, 2023 and 2022 was $ 60,752 and $ 61,403 respectively, including $ 3,255 and $ 3,171 respectively
for Therapy Devices which is allocated to Cost of Sales.

 9.
 EQUITY

 Equity
Transactions

 On
April 1, 2023 and 2022 the Company issued 101,663 shares of Common Stock to Ricardo Komotar (RJK Consulting), a consultant, in accordance
with the terms of a consulting agreement (see Note 13).

the years ended December 31, 2023 and 2022, under the terms of the Consulting Agreement referred to in Note 13, the Company issued 0
and 1,607,142 of Common Stock to Fountainhead valued at $ 0 and $ 171,428, respectively.

each of the years ended December 31, 2023 and 2022, the Company accrued an aggregate of $ 324,370 of dividends in respect of Company Series
D Convertible Preferred shares.

 Equity
Classes

 Our
authorized capital stock consists of 55,000,000 shares of common stock, par value $ 0.0001 per share, and 10,000,000 shares of preferred
stock, par value $ 0.0001 per share, the rights and preferences of which may be established from time to time by our board. As at December 31, 2023, there were 32,628,835 shares of common stock, one ( 1) share of Series C Preferred Stock and 270,306 shares of Series D Preferred
Stock outstanding.

 Holders
of our common stock are entitled to one vote for each share on all matters voted upon by our stockholders, including the election of
directors, and do not have cumulative voting rights. Subject to the rights of holders of any then outstanding shares of our preferred
stock, our common stockholders are entitled to any dividends that may be declared by our board. Holders of our common stock are entitled
to share ratably in our net assets upon our dissolution or liquidation after payment or provision for all liabilities and any preferential
liquidation rights of our preferred stock then outstanding. Holders of our common stock have no preemptive rights to purchase shares
of our stock. The shares of our common stock are not subject to any redemption provisions and are not convertible into any other shares
of our capital stock. All outstanding shares of our common stock are, and the shares of common stock to be issued in the offering will
be, upon payment therefor, fully paid and non-assessable. The rights, preferences and privileges of holders of our common stock will
be subject to those of the holders of any shares of our preferred stock we may issue in the future.

 Series
C Convertible Preferred Stock shares ("Preferred C Stock") are convertible (at the Holder's option or mandatorily upon
the occurrence of certain events) into 14,815 shares of the Company's Common Stock (at $ 3.75 per share). The Preferred C Stock
carries no dividend or other rights.

 Series
D Convertible Preferred shares ("Preferred D Stock") are convertible into Company Common Shares at a price of $ 2.15. The
Series D carry a cumulative preferred dividend of 12 % per annum, payable in cash. The Company is able to redeem the Series D at par at
any time, at its sole option.

 10.
 STOCK-BASED COMPENSATION

 The
Company from time-to-time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees.
Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their
fair value, which is measured as of the "measurement date" using an option pricing model, or their contractual value if different
in the case of common stock. The "measurement date" for options and warrants related to contracts that have substantial disincentives
to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants
is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option
or warrant.

 Non-Employee
Stock Compensation

 Aggregate
stock-based compensation for shares of common stock granted to non-employees for the years ended December 31, 2023 and 2022 was $ 10,141
and $ 185,610, respectively. $ 171,428 in 2022 was in respect of the Fountainhead Consulting Agreement (see Notes 13 and 14). As of December
31, 2023, there was $ 0 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.

 11.
 INCOME TAXES

 Loss
Before Taxes

 SUMMARY OF LOSS BEFORE TAXES

 2023

 2022

 Domestic

 $
 ( 42,829
)

 $
 ( 382,553
)

 Foreign

 ( 26,862
)

 ( 22,364
)

 Loss
 Before Taxes

 $
 ( 69,691
)

 $
 ( 404,917
)

 The
reconciliation of income tax expense (credit) at the U.S. statutory rate of 21 %, to the Company's effective tax rate is as follows:

 SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSE STATUTORY RATE

 2023

 2022

 Year Ended December 31,

 2023

 2022

 US statutory rate

 $
 ( 14,635
)

 $
 ( 85,033
)

 Tax difference between foreign and U.S.

 ( 289
)

 ( 204
)

 Change in Valuation Allowance

 ( 14,924
)

 ( 85,237
)

 Tax Provision

 $
 -

 $
 -

 Deferred
Income Taxes

 The
Company has operations in the US, Germany and the UK and incurred net operating losses since inception. The Company has not reflected
any tax benefit related to such net operating losses in the financial statements. Prior to August 15, 2007 the Company's US operating
entity was a limited liability company and losses were passed through to the individual members, therefore the Company only has potential
tax benefits from the date it became a 'C' corporation.

 Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. Significant components of the Company and its subsidiaries' deferred
tax assets at December 31, 2023 and December 31, 2022 are as follows:

 SCHEDULE OF DEFERRED TAX ASSETS

 2023

 2022

 Operating loss carry-forward – US

 $
 19,888,000

 $
 19,881,000

 Operating loss carry-forward – Foreign

 $
 1,630,000

 $
 1,656,000

 Deferred tax asset before Valuation allowance – US

 4,176,000

 4,175,000

 Deferred tax asset before Valuation allowance – Foreign

 485,000

 497,000

 Valuation allowance

 ( 4,661,000
)

 ( 4,672,000
)

 Net deferred tax asset

 $
 —

 $
 —

 In
assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of
the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future
taxable income.

 The
authoritative guidance requires a valuation allowance to reduce the deferred tax assets recorded if, based on the weight of the evidence,
it is more likely than not that some portion or all of the deferred tax assets will not be realized. Furthermore, in circumstances in
which management has determined that existing conditions or events raise substantial doubt about its ability to continue as a going concern
the authoritative guidance requires that a valuation allowance should be recorded for all deferred tax assets. Accordingly, management
has determined that a 100 % valuation allowance is appropriate at December 31, 2023 and December 31, 2022.

 The
U.S. Tax Cuts and Jobs Act (Tax Act) was enacted on December 22, 2017 and introduces significant changes to U.S. income tax law. Effective
in 2018, the Tax Act reduces the U.S. statutory tax rate from 35% to 21% and creates new taxes on certain foreign-sourced earnings and
certain related-party payments, which are referred to as the global intangible low-taxed income tax and the base erosion tax, respectively.
The Tax Act requires us to pay U.S. income taxes on accumulated foreign subsidiary earnings not previously subject to U.S. income tax
at a rate of 15.5 % to the extent of foreign cash and certain other net current assets and 8 % on the remaining earnings. Since the Company's
foreign subsidiaries have not generated taxable income and have no accumulated earnings, the Company believes that the Tax Act will not
have a significant impact on the Company's consolidated financial statements.

 Net
Operating Loss Carry-Forwards

 As
of December 31, 2023 and 2022, the Company had U.S. accumulated losses for tax purposes of approximately $ 19,888,000 and $ 19,881,000
respectively, which may be carried forward and offset against U.S. taxable income, and expire during the tax years 2029 through 2041.

 Federal
tax laws impose significant restrictions on the utilization of net operating loss carry-forwards and in the event of a change in ownership
of the Company, as defined by the Internal Revenue Code Section 382. The Company's net operating loss carry-forwards may be subject
to the above limitations.

 As
of December 31, 2023 and 2022, the Company had German accumulated losses for tax purposes of approximately $ 1,392,000 and $ 1,450,000
respectively, which may be carried forward and offset against German taxable income subject to certain restrictions and limitations in
the event of changes in the NovaVision GmbH's ownership. As disclosed in Note 3, the Company is in the process of winding down
the entity, following which these tax losses will no longer be available.

 As
of December 31, 2023 and 2022, the Company had UK accumulated losses for tax purposes of approximately $ 238,000 and $ 206,000 respectively,
which may be carried forward and offset against UK taxable income subject to certain restrictions and limitations.

 Tax
Rates

 The
applicable US income tax rate for the Company for both of the years ended December 31, 2023 and 2022 was 21 %. Non-US subsidiaries are
taxed according to the tax laws in their respective country of residence. The German applicable rate for both of the years ended December
31, 2023 and 2022 was 31.58 %; the UK applicable rate for smaller companies for both the years ended December 31, 2023 and 2022 was 19 %.

 If
any earnings were distributed to US in the form of dividends or otherwise, after the repayment of intercompany debt, the Company would
be subject to additional US income taxes (subject to an adjustment for foreign tax credits) and foreign withholding taxes.

 Uncertain
Tax Position

 The
Company has recorded no liability for income taxes associated with unrecognized tax benefits at the date of adoption and has not recorded
any liability associated with unrecognized tax benefits during 2023 and 2022. Accordingly, the Company has not recorded any interest
or penalty in regard to any unrecognized benefit.

 12.
 COMMITMENTS AND CONTINGENCIES

 Lease

 The
Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent
of approximately $ 4,300 per month, plus other charges of approximately $ 2,700 per month. The lease terminated on August 31, 2023 and
was extended for a further three years and four months to December 31, 2026. Rent expense for the years ended December 31, 2023 and 2022
was $ 74,464 and $ 79,314 respectively.

 The
table below provides the future lease payments each year until the lease expiration date:

 SCHEDULE OF FUTURE LEASE PAYMENTS

 Future
Lease Payments

 Year

 Liability

 2024

 $
 51,576

 2025

 $
 52,092

 2026

 $
 53,655

 Potential
German tax liability

 In
June 2012 the Company's NovaVision German subsidiary received a preliminary assessment for Magdeburg City trade tax of 75,000
(approximately $ 82,000), with an additional interest charge of 12,000 (approximately $ 13,200). This assessment is for the 2010
fiscal year and relates to the Company's acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate
tax for the same period was preliminarily reduced to zero. The Company did not accept this trade tax assessment and appealed against
it to the relevant tax authorities with a view to its reduction. The relevant tax authorities agreed to suspend the assessment pending
the outcome of certain court hearings and proposed tax legislation, and the Company agreed to make monthly payments on account totaling
 75,000 (approximately $ 82,000) which were completed in October 2016 and fully expensed. At that time the Company appealed against
the interest charge of 12,000 (approximately $ 13,200) which the tax authorities did not accept but also agreed to suspend pending
the outcome of the hearings and proposed legislation outlined above. Accordingly, the Company has made no provision for this liability
in the years ended December 31, 2023 and 2022 respectively. The Company is in the process of winding down the entity, as disclosed in
Note 3.

 13.
 CONSULTING AND OTHER AGREEMENTS

 The
following agreements remained in force during the years ended December 31, 2023 and 2022:

 Consulting
Agreement with Fountainhead

 In
March 2017 and effective April 1, 2017, the Company amended the Fountainhead Consulting Agreement. Under the Amended Agreement, fees
of $ 450,000 were payable to Fountainhead in Company Common Stock issued at the higher of $ 0.21 and the average price for the 30 days
prior to issuance, and deliverable at the end of each fiscal quarter. This was amended slightly effective January 1, 2021 ("the
Amended Agreement"). Under the Amended Agreement, fees are payable to Fountainhead in Company Common Stock ("Shares")
as follows: 1) 535,714 Shares on the last day of each quarter; or 2) if the average closing price of the Shares for the 30 trading days
prior to issuance is above $ 0.21, a number of Shares calculated by dividing $ 112,500 by the average closing price of the Shares for the
30 trading days prior to issuance. Under the terms of the Amended Agreement, Fountainhead continued to provide the executive management
team of the Company, including the positions of CEO, President and CFO, whose employment agreements with the Company stipulate they receive
no remuneration from the Company.

 Effective
October 1, 2022 the Amended Agreement was terminated by Fountainhead and the Company by mutual agreement. Effective the same date the
Company entered into revised employment agreements with Peter Zachariou, David Cantor and Adrian Liddell under which they would continue
as CEO, President and CFO respectively as individuals and not as representatives of Fountainhead; there is no compensation payable under
the employment agreements.

the years ended December 31, 2023 and 2022 the Company issued 0 and 1,607,142 shares of Common Stock to Fountainhead for fees of $ 0 and
$ 171,428, respectively.

 Other
Agreements

 On
March 30, 2021, Vycor entered into a Consulting Agreement with Ricardo J. Komotar, M.D. (the "Agreement") to provide certain
specified services over the three-year term of the Agreement. Under the Agreement, Dr. Komotar will provide general scientific advisory
consultancy services, and will also provide scientific advisory services based around certain specific pre-determined milestones. In
consideration of the Consultant's services, the Company agreed to deliver to the Consultant over the course of the three-year term,
a total of 304,989 shares of Company Common Stock in respect of the general consultancy, and up to 1,219,957 shares of Company Common
Stock in respect of the milestones. On April 1, 2023 and 2022 101,663 shares of Company Common Stock (valued at $ 9,455 and $ 12,200, respectively)
were issued under the terms of the Agreement, which is being amortized over twelve months.

 14.
 RELATED PARTY TRANSACTIONS AND BALANCES

 Peter
Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at December 31, 2023, 62.3 %
of the Company's Common Stock and 69.7 % of the Company's Series D Preferred Stock. Adrian Liddell, Chairman, is a consultant
to Fountainhead. Peter Zachariou owns 0.15 % of the Company's Common Stock and 25.7 % of the Company's Series D Preferred Stock.

each of the years ended December 31, 2023 and 2022, under the terms of the Consultancy Agreement referred to in Note 14, the Company
issued 0 and 1,607,142 shares of Common Stock to Fountainhead for fees of $ 0 and $ 171,428, respectively.

the years ended December 31, 2023 and 2022, respectively, the Company issued unsecured loan notes to Fountainhead for a total of $ 0 and
$ 172,500, respectively. The loan notes bear interest at a rate of 10 % and are due on demand or by their one-year anniversary (see Note
6).

the years ended December 31, 2023 and 2022, respectively, the Company accrued interest on related party loans of $ 49,515 and $ 39,563,
respectively.

each of the years ended December 31, 2023 and 2022, the Company accrued an aggregate of $ 324,370 of Preferred D Stock dividends, of which
$ 226,037 was regarding Fountainhead and $ 83,386 was regarding Peter Zachariou. Total accrued Preferred D Stock dividends at December
31, 2023 and 2022 was $ 2,270,590 and $ 1,946,220, respectively, of which $ 1,582,260 and $ 1,356,224, respectively, was regarding Fountainhead
and $ 583,701 and $ 500,315, respectively, was regarding Peter Zachariou.

 15.
 CONCENTRATION

 Vycor
Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn
sell to hospitals.

 SCHEDULE OF CONCENTRATION

 Sales Concentration

 Year ended December 31,

 2023

 2022

 Number of customers over 10%

 Percentage of sales

 %

 %

 Accounts
Receivable Concentration

 At December 31,

 2023

 2022

 Number of customers over 10%

 Percentage of accounts receivable

 %

 %

 The
Company has three sub-contract manufacturers from which it purchases, respectively, VBAS injection molded parts, completed and sterilized
VBAS units, and extension arms. Purchases from these manufacturers vary from quarter to quarter, with no purchases in some quarters,
however on an annual basis purchases from each manufacturer represent over 10 % of total annual purchases.

 16.
 SUBSEQUENT EVENTS

 The
Company has evaluated the existence of events and transactions subsequent to the balance sheet date through the date the consolidated
financial statements were issued and has determined that, other than that disclosed above, there were no significant subsequent events
or transactions that would require recognition or disclosure in the financial statements.

 ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 None.

 ITEM
9A. CONTROLS AND PROCEDURES.

 a)
 Disclosure Controls and Procedures

 We
are required to maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in
our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time
periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated
to our management, including our chief executive officer (also our principal executive officer) and our chief financial officer (also
our principal financial and accounting officer) to allow for timely decisions regarding required disclosure.

 Pursuant
to Rule 13a-15(b) under the Securities Exchange Act of 1934 ("Exchange Act"), the Company's management, including the
Company's Chief Executive Officer ("CEO") (the Company's principal executive officer) and Chief Financial Officer
("CFO") (the Company's principal financial and accounting officer), has evaluated the effectiveness of the Company's
disclosure controls and procedures (as defined under Rule 13a-1) under the Exchange Act) as of the end of the period covered by
this report. Based on such evaluation, our CEO and our CFO have concluded that a material weakness occurred as of April 1, 2021 and has
continued to have a weakness through the present date, on account of the resignation of the independent members of the Company's
Audit Committee as of that date. Effective that date, our disclosure and controls were no longer effective to ensure that information
required to be disclosed by the Company in the reports it files or submits under the Exchange Act is accumulated and communicated to
the Company's management, including its CEO and its CFO, as appropriate, to allow timely decisions regarding required disclosure.

 The
matter involving internal controls and procedures that our management considered to be a material weakness under the standards of the
Public Company Accounting Oversight Board was a lack of a functioning audit committee with independent members, resulting in ineffective
oversight in the establishment and monitoring of required internal controls and procedures.

 Management
believes that the material weakness set forth did not have an effect on our financial results. However, management believes that the
lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors, results in ineffective
oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement
in our financial statements in future periods.

 b)
 Management's Report on Internal Control over Financial Reporting

 Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed
by, or under the supervision of, the company's principal executive and principal financial officers and effected by the company's
board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the
United States of America and includes those policies and procedures that:

 Pertain
 to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets
 of the company;

 Provide
 reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
 accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being
 made only in accordance with authorizations of management and directors of the company; and

 Provide
 reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's
 assets that could have a material effect on the financial statements.

 Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed,
have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect
to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material
misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent
limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to
reduce, though not eliminate, this risk.

 We
carried out an assessment, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness
of the design and operation of our internal controls over financial reporting, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities
Exchange Act of 1934, as of December 31, 2023. In making this assessment, management used the criteria set forth by the Committee of
Sponsoring Organizations of the Treadway Commission in Internal Control — Integrated Framework (2013). Based on that assessment
and on those criteria, our CEO and CFO concluded that our internal control over financial reporting was not effective as of December
31, 2023 due to the a lack of a functioning audit committee with independent members, resulting in ineffective oversight in the establishment
and monitoring of required internal controls and procedures.

 This
annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial
reporting. Management's report was not subject to attestation by our registered public accounting firm pursuant to temporary rules
of the SEC that permit us to provide only the management's report in this annual report.

 c)
 Changes in Internal Controls

 There
have been no changes in the Company's internal control over financial reporting (as such term is defined in Rules 13a-15(f) under
the Exchange Act) during the fiscal period to which this report relates that have materially affected, or are reasonably likely to materially
affect, the Company's internal control over financial reporting.

 The
Company's management, including the Company's CEO and CFO, do not expect that the Company's internal control over financial
reporting will prevent all errors and all fraud. Because of its inherent limitations, internal control over financial reporting may not
prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may
deteriorate.

 ITEM
9B. OTHER INFORMATION.

 None

 PART
III

 ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 Our
Directors and Executive Officers

 Set
forth below is certain biographical information concerning our current executive officers and directors. We currently have two executive
officers as described below.

 Directors
 and Executive Officers

 Position/Title

 Age

 Peter
 C. Zachariou

 Chief
 Executive Officer and a Director

 David
 Marc Cantor

 President
 and a Director

 Adrian
 Christopher Liddell

 Chairman
 of the Board, Chief Financial Officer and a Director

 Peter
C. Zachariou was appointed a Director of the Company in May 2010, Executive Vice President in September 2010 and Chief Executive
Officer on January 2, 2014. As CEO, he has responsibility for the sales, marketing and customer functions of both the Vycor and NovaVision
divisions. For the past 30 years, Mr. Zachariou has been an active investor in and proprietor of a variety of companies and industries,
predominantly in U.S. emerging and growth companies across a broad range of industry sectors. He is an investment manager for Fountainhead
Capital Management Limited, an investment company based in Jersey, Channel Islands.

 David
Marc Cantor has been President of the Company since September 2010 and a Director since January 2010. As President he is responsible
for the clinical, product development and manufacturing functions of both the Vycor and NovaVision divisions, as well as their patent
and trademark portfolios. Mr. Cantor has over 22 years of experience in Investment Banking with a focus on Mergers and Acquisitions and
Equity Capital Raisings. From 2001 – 2005 he was at Citigroup Capital Markets where he was Co-head of its M&A European Business
Development Group and subsequently European Head of its Diversified Industrials and Aerospace activities. Prior to Citigroup he was a
Managing Director in M&A at Donaldson Lufkin & Jenrette and worked at Lehman Brothers both in New York and London in both the
Equity Capital and M&A groups. He is an investment manager of Fountainhead Capital Management Limited, an investment company based
in Jersey, Channel Islands. Mr. Cantor has a BSc with Honours from City Business School, London.

 Adrian
Christopher Liddell has been Chairman of the Board and a Director of the Company since January 2010, and serves as the Company's
CFO. As CFO he is responsible for the financial operation of the company, as well as regulatory and legal matters. Mr. Liddell has over
40 years of strategic, corporate and financial advisory and company investment experience. From 2003 to 2006, Mr. Liddell was an investment
advisor at Phoenix Equity Partners, a European private equity fund. From 1998 to 2003 Mr. Liddell served as Managing Director, Mergers
& Acquisitions, at Donaldson Lufkin & Jenrette and then Citigroup in London. From 1984 to 1998 Mr. Liddell held various positions
in mergers & acquisitions and corporate finance at Lehman Brothers and Samuel Montagu & Co, in London. He is also an advisor
to Fountainhead Capital Management Limited, an investment company based in Jersey, Channel Islands, Mr. Liddell qualified as a Chartered
Accountant in 1984 with Arthur Young (now Ernst & Young) and holds an MA, Hons. from Christ's College, University of Cambridge.

 All
of our directors hold office until the next annual meeting of stockholders and until their respective successors have been elected or
qualified. Officers serve at the discretion of the board of directors. There are no family relationships among our directors or executive
officers. There is no arrangement or understanding between or among our officers and directors pursuant to which any director or officer
was or is to be selected as a director or officer, and there is no arrangement, plan or understanding as to whether non-management stockholders
will exercise their voting rights to continue to elect the current board of directors.

 None
of our directors and executive officers have during the past five years:

 had
 any bankruptcy petition filed by or against any business of which he was a general partner or executive officer, either at the time
 of the bankruptcy or within two years prior to that time;

 been
 convicted in a criminal proceeding and is not subject to a pending criminal proceeding;

 been
 subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
 permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities,
 futures, commodities or banking activities;

 or
 been found by a court of competent jurisdiction (in a civil action), the Securities Exchange Commission or the Commodity Futures
 Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended
 or vacated.

 Board
Committees

 Given
that the Company has only three incumbent directors, none of whom are independent, the Board of Directors does not maintain any Board
Committees as of this date, with the Audit Committee comprising the whole Board.

 Section
16(a) Beneficial Ownership Reporting Compliance

 Pursuant
to Section 16(a) of the Exchange Act and the rules thereunder, the Company's executive officers and directors and persons who own
more than 10% of a registered class of the Company's equity securities are required to file with the SEC reports of their ownership
of, and transactions in, the Company's common stock.

 ITEM
11. EXECUTIVE COMPENSATION.

 The
following is a summary of the compensation we paid for each of the last two years ended December 31, 2023 and 2022, respectively (i)
to the persons who acted as our principal executive officer during our fiscal year ended December 31, 2023 and (ii) to the person who
acted as our next most highly compensated executive officer other than our principal executive officer who was serving as an executive
officer as of the end of our last fiscal year.

 Name

 and

 Principal

 Position

 Year

 Salary ($)

 Bonus
 ($)

 Stock
 Awards ($)

 Option
 Awards ($)

 Non-

 Equity
 Incentive

 Plan
 Compensation

 Non-

 Qualified
 Deferred Compensation Earnings

 ($)

 All

 other
 Compensation ($)

 Total
 ($)

 Peter
 Zachariou

 CEO

 2023

 2022

 $

 $

 —

 —

 —

 —

 —

 —

 —

 —

 David
 Cantor President

 2023

 2022

 $

 $

 —

 —

 —

 —

 —

 —

 —

 —

 OUTSTANDING
EQUITY AWARDS

 Grants
of Plan-Based Awards

 Equity Compensation Plan Information

 Plan category

 Number of securities to be issued upon exercise of outstanding options, warrants and rights (1)

 Weighted- average exercise price of outstanding options, warrants and rights

 Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (1)

 Equity compensation plans approved by security holders

 3,390,000

 $
 -

 3,390,000

 Equity compensation plans not approved by security holders

 -

 -

 -

 Total

 3,390,000

 $
 -

 3,390,000

 (1)

 As
 of December 31, 2023.

 Warrants
Issued to Management

 Name

 Grant
 Date

 Number of Securities
 Underlying
 Unexercised
 Exercisable Warrants

 Number of Securities
 Underlying
 Unexercised
 Exercisable Warrants

 Warrant Exercise
 Price ($)

 Warrant Expiration
 Date

 None

 Total

 Employment
Agreements

 Effective
January 2, 2014, the Company entered into amended employment agreements with Peter Zachariou and David Cantor to serve as the Company's
Chief Executive Officer and President respectively as appointees of Fountainhead; and an employment agreement with Adrian Liddell to
serve as the Company's Chief Financial Officer as appointee of Fountainhead; these agreements were further amended in March 2017.
Each agreement continued for a period of twelve months and was then automatically extended unless terminated by either party. As appointees
of Fountainhead under the Fountainhead Consulting Agreement no compensation was payable under the employment agreements. Effective October
1, 2022, the Fountainhead Consulting Agreement was terminated by Fountainhead and the Company by mutual agreement and the Company entered
into revised employment agreements with Peter Zachariou, David Cantor and Adrian Liddell under which they would continue as CEO, President
and CFO respectively as individuals and not as representatives of Fountainhead; there continues to be no compensation payable under the
employment agreements.

 Compensation
of Directors

 Not
applicable

 ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 The
following table sets forth certain information with respect to the beneficial ownership of our voting securities by (i) any person or
group owning more than 5% of any class of voting securities, (ii) each director, (iii) our chief executive officer and president and
(iv) all executive officers and directors as a group as of March 31, 2024. Unless noted, the address for the following beneficial owners
and management is 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487.

 Title of Class

 Name and Address of

 Beneficial Owner

 Amount and Nature of
 Beneficial Owner (1)

 Percent of
 Class (2)

 Common Stock

 Peter C. Zachariou

 48,856

 0.15
 %

 Series D Preferred Stock

 Peter C. Zachariou

 69,487

 25.71
 %

 Common Stock

 All executive officers and directors as a group

 48,856

 0.15
 %

 Series D Preferred Stock

 All executive officers and directors as a group

 69,487

 25.71
 %

 Common Stock

 Fountainhead Capital Management Limited 13 Castle Street, St. Helier, Jersey JE2 3BT

 20,340,520

 62.34
 %

 Series D Preferred Stock

 Fountainhead Capital Management Limited 13 Castle Street, St. Helier, Jersey JE2 3BT

 188,363

 69.69
 %

 (1)
In determining beneficial ownership of our Common Stock and Series D Preferred Stock, the number of shares shown includes shares which
the beneficial owner may acquire upon exercise of debentures, warrants and options which may be acquired within 60 days. In the case
of directors, the number of shares includes shares granted but not issued under the director's Deferred Compensation Plan. In determining
the percent of Common Stock or Series D Preferred Stock owned by a person or entity on April 15, 2024, (a) the numerator is the number
of shares of the class beneficially owned by such person or entity, including shares which the beneficial ownership may acquire within
60 days of exercise of debentures, warrants and options, and the issuance of shares granted but not issued under the director's
Deferred Compensation Plan; and (b) the denominator is the sum of (i) the total shares of that class outstanding on April 15, 2024 (32,628,835
shares of Common Stock and 270,306 shares of Series D Preferred Stock) and (ii) the total number of shares that the beneficial owner
may acquire upon exercise of the debentures, warrants and options or that can be issued under the director's Deferred Compensation
Plan. Unless otherwise stated, each beneficial owner has sole power to vote and dispose of its shares.

 ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 Related
Party Transactions

 Peter
Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at December 31, 2023, 62.3%
of the Company's Common Stock and 69.7% of the Company's Series D Preferred Stock. Adrian Liddell, Chairman, is a consultant
to Fountainhead. Peter Zachariou owns 0.15% of the Company's Common Stock and 25.7% of the Company's Series D Preferred Stock.

each of the years ended December 31, 2023 and 2022, under the terms of the Consultancy Agreement referred to in Note 13 the Company
issued 0 and 1,607,142 shares of Common Stock to Fountainhead for fees of $0 and $171,428, respectively.

the years ended December 31, 2023 and 2022, respectively, the Company issued unsecured loan notes to Fountainhead for a total of $0 and
$172,500, respectively. The loan notes bear interest at a rate of 10% and are due on demand or by their one-year anniversary (see Note
6).

the years ended December 31, 2023 and 2022, respectively, the Company accrued interest on related party loans of $49,515 and $39,563,
respectively.

each of the years ended December 31, 2023 and 2022, the Company accrued an aggregate of $324,370 of Preferred D Stock dividends, of which
$226,037 was regarding Fountainhead and $83,386 was regarding Peter Zachariou. Total accrued Preferred D Stock dividends at December
31, 2023 and 2022 was $2,270,590 and $1,946,220, respectively, of which $1,582,260 and $1,356,224, respectively, was regarding Fountainhead
and $583,701 and $500,315, respectively, was regarding Peter Zachariou.

 Director
Independence

 As
of April 16, 2024, our three (3) directors are not considered "independent".

 ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

 Audit
Fees

 The
aggregate fees billed by our principal accountant for the audit of our annual financial statements, review of financial statements included
in the quarterly reports and other fees that are normally provided by the accountant in connection with statutory and regulatory filings
or engagements for the fiscal years ended December 31, 2023 and December 31, 2022, respectively, were approximately $71,500 and $65,000.

 Tax
Fees

 The
fees billed for professional services rendered by our principal accountant for tax compliance, tax advice and tax planning for the fiscal
years ended December 31, 2023 and 2022 were $4,400 and $4,000 respectively.

 All
Other Fees

 There
were no fees billed for other products or services provided by our principal accountant for 2023 or 2022.

 PART
IV

 ITEM
15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 The
following documents are filed as part of this 10-K:

 1.
FINANCIAL STATEMENTS

 The
following documents are filed in Part II, Item 8 of this annual report on Form 10-K:

 Reports of Prager Metis CPAs, LLC., Independent Registered Certified Public Accounting Firm (PCAOB ID: 273)

 Consolidated Balance Sheets as of December 31, 2023 and 2022

 Consolidated Statements of Comprehensive Loss for the years ended December 31, 2023 and 2022

 Consolidated Statements of Stockholders' Deficiency from January 1, 2022 to December 31, 2023

 Consolidated Statement of Cash Flows for the years ended December 31, 2023 and 2022

 Notes to Consolidated Financial Statements

 2.
FINANCIAL STATEMENT SCHEDULES

 All
financial statement schedules have been omitted as they are not required, not applicable, or the required information is otherwise included.

 3.
EXHIBITS

 The
exhibits listed below are filed as part of or incorporated by reference in this report.

 Exhibit
 No.

 Identification
 of Exhibit

 31.1

 Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 31.2

 Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 32.1

 Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 32.2

 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 101.INS#

 101.SCH#

 101.CAL#

 101.DEF#

 101.LAB#

 101.PRE#

 Cover

 SIGNATURES

 Pursuant
to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

 Vycor
 Medical, Inc.

 (Registrant)

 By:

 /s/
 Peter C. Zachariou

 Peter
 C. Zacharion

 Chief
 Executive Officer and Director (Principal Executive Officer)

 Date

 By:

 /s/
 Adrian Liddell

 Adrian
 Liddell

 Chairman
 of the Board and Director

 (Principal
 Financial and Accounting Officer)

 Date

 Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the
registrant and in the capacity and on the date indicated.

 By:

 /s/
 Peter C. Zachariou

 Peter
 C. Zachariou

 Chief
 Executive Officer and Director

 Date

 By:

 /s/
 David Marc Cantor

 David
 Marc Cantor

 President
 and Director (Principal Executive Officer)

 Date

 By:

 /s/
 Adrian Christopher Liddell

 Adrian
 Christopher Liddell

 Chairman
 of the Board and Director (Principal Financial and Accounting Officer)

 Date